EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu
EyePoint’s shares fell over 70% after its phase 3 readout for Duravyu, a drug-device combo for wet age-related macular degeneration, missed a primary endpoint versus Regeneron’s Eylea. EyePoint cited non-wAMD related vision loss in 9 of 211 patients and said an ad hoc analysis showed non-inferiority. Lucia trial is due this fall.
How this was made
The 30-second read
Why it matters
The phase 3 miss on a primary BVCA endpoint increases probability of regulatory delay or failure, while the company’s reliance on an ad hoc analysis shifts focus to whether the second late-stage readout (Lucia) can confirm efficacy and resolve safety questions.
Market read
This is a catalyst-driven biotech event: a phase 3 primary endpoint miss with a specific safety confound, followed by heightened expectations for the next trial readout.
What to watch
Investors may be underweighting the need to explain the mechanism behind the 4% unrelated vision loss and how regulators will view the ad hoc exclusion approach.
Background
EyePoint is developing Duravyu, a drug-device combo using a sustained-release ocular implant delivering vorolanib, aiming to match anti-VEGF efficacy with fewer injections.
Ticker impact
EyePoint shares plunged after Duravyu’s phase 3 wAMD readout missed on BVCA, with vision loss unrelated to wAMD driving an ad hoc salvage.
Near-term downside pressure likely persists until Lucia data clarifies whether the non-wAMD vision loss was an isolated anomaly.
The article reports a primary endpoint miss in phase 3 and highlights a specific safety/endpoint confound that must be explained before approval odds improve.
Market effects
Raises perceived clinical-trial execution risk for ophthalmology drug-device combos and keeps attention on late-stage readouts in wAMD.
Primarily US small/mid-cap biotech sentiment spillover; limited direct regional macro linkage.
wAMD competitive dynamics remain global, but the immediate impact is company-specific to EyePoint and its near-term trial calendar.
Counterpoint
If the non-wAMD vision loss was true “bad luck,” the ad hoc non-inferiority result and strong secondary endpoints could still support a viable approval path.
Key entities
- companyEyePoint Pharmaceuticals
Subject of the article; shares fell after Duravyu’s first phase 3 wAMD readout missed on the primary endpoint.
- productDuravyu
EyePoint’s drug-device combo (vorolanib implant) tested against Eylea in phase 3.
- comparatorEylea (aflibercept)
Standard-of-care anti-VEGF referenced as the benchmark for non-inferiority and injection burden.
- clinical_programLucia trial
Second phase 3 readout expected this fall, now central to the approval narrative.
